Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Biomedical Advanced Research and Development Authority (BARDA) has granted $21m to Vaxin for pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an IND filing of AdVAV, company's new anthrax vaccine.
Subscribe to our email newsletter
The funding will also support the company in conducting a first-in-man dose ranging study to evaluate the anthrax vaccine.
Vaxin president and CEO Bill Enright said this is a great opportunity for Vaxin to apply their vaccine development experience to a critical need and they thank the team at BARDA for this contract to advance this potentially important new technology.